A fast growing sector with strong products and players - but what will the COPD/Asthma landscape look like 5 years from now?
The global asthma and COPD market is currently worth around US$20 billion.
The top twelve pharmaceutical products by value had combined global sales of
US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion.
Combined sales of the top ten products were 21.1% higher than in 2004.
A number of older therapies, for asthma in particular, are widely available
generically and there is fierce competition in the market. The asthma market
accounts for the majority of the total and is valued at around US$15 billion.
The COPD market is currently valued at US$4 - US$5 billion and is set to
double in the next five years.
Future market growth will be driven by increasing disease awareness, an
increasing patient pool, both in the paediatric asthma sector and the ageing
population susceptible to COPD, and the launch of newer, more expensive
therapies targeting areas of high unmet clinical need. These will be offset
to some extent by the launch of new generics and the sales erosion of
monotherapies by combination products.
This report provides a complete insight to the prospects for companies and products that are driving this high growth US$20 billion sector.
Table of Contents
Foreword
Executive Summary
What are Asthma and COPD?
Morbidity and Mortality
Diagnosis and Treatment
Asthma Management
COPD Management
Pharmacotherapy
Current Market Leaders
Drugs in the Pipeline
Competitor Ratio Analysis
Short-Acting Beta-2 Agonists
Xopenex (levalbuterol)
Sales Forecast
Patent Challenges
Clinical Trials
Xopenex versus racemic albuterol in COPD
Xopenex HFA study
Xopenex in the emergency room
Inhaled Corticosteroids
Flixotide/Flovent (fluticasone propionate)
Sales Forecasts
Clinical Trials
Pulmicort (budesonide)
Sales Forecast
Patent Challenge
Clinical Trials
START - budesonide during pregnancy
START - budesonide in children with mild persistent asthma
START - safety outcome data
EUROSCOP
Long-term data from early intervention study in Finland
Asmanex (mometasone furoate)
Sales Forecasts and Assumptions
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Clinical Trials
Patients previously maintained on bronchodilators alone
Patients previously maintained on inhaled corticosteroids
Patients previously maintained on oral corticosteroids
Alvesco (ciclesonide)
Sales Forecast and Assumptions
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Clinical trials
Ciclesonide versus fluticasone propionate
Low incidence of oropharyngeal side effects
Ciclesonide versus budesonide and fluticasone
Intranasal formulation
Ciclesonide versus budesonide
Muscarinic Antagonists
Spiriva (tiotropium)
Sales Forecast and Assumptions
Competitor Ratio Analysis
Novelty/rationale for mechanism of action
Proof of concept/clinical data
Management/clinical expertise
Competition within marketplace
Risks associated with drug development in therapeutic class
Clinical Trials
Pooled Studies
Study on COPD patients in France
Spiriva+formoterol versus salmeterol+fluticasone propionate
